Molecular markers for response prediction in locally advanced rectal cancer: Is individualized therapy coming?;Molekulare Marker zur Responseprädiktion beim lokal fortgeschrittenen Rektumkarzinom: Kommt die Individualisierung der Therapie?

Onkologe

Volumn 16, Issue 8, 2010, Pages 779-788

  Liersch, T ^a   Gaedcke, J ^a   Grade, M ^a   Sprenger, T ^a   Conradi, L ^a   Becker, H ^a   Ghadimi, B M ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Genetic profile; Microarray technology; Radiochemotherapy; Tumor biology; Tumor response

Indexed keywords

FLUOROURACIL; TUMOR MARKER;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CANCER STAGING; CLINICAL TRIAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; PHENOTYPE; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; RECTUM CANCER; REVIEW; TREATMENT RESPONSE;

EID: 77957320185     PISSN: 09478965     EISSN: 14330415     Source Type: Journal    
DOI: 10.1007/s00761-010-1866-y     Document Type: Review

References (30)

1. Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61-70
2. Ayers M, Symmans WF, Stec J et al (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22:2284-2293
3. Bengala C, Bettelli S, Bertolini F et al (2009) Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 20:469-474
4. Bertagnolli M (2009) The forest and the trees: pathways and proteins as colorectal cancer biomarkers. J Clin Oncol 27:5866-5867 (Editorial)
5. Bertolini F, Bengala C, Losi L et al (2007) Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 68:1455-1461
6. Bonnefoi H, Potti A, Delorenzi M et al (2007) Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 8:1071-1078
7. Bosset JF, Collete L, Calais G et al (2006) Chemoradiotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114-1123
8. Bostner J, Ahnstrom WM, Fornander T et al (2007) Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 26:6997-7005
9. Bujko K, Glynne-Jones R, Bujko M (2010) Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomized trials. Ann Oncol (Epub ahead of print)
10. Bujko K, Michalski W, Kepka L et al (2007) Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: an analysis of outcomes in a randomized trial. Int J Radiat Oncol Biol Phys 67:369-377
11. Capirci C, Valentini V, Cionini L et al (2008) Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 56 ypCR patients. Int J Rad Oncol Biol Phys 72:99-107
12. Chan AK, Wong A, Jenken D et al (2005) Posttreatment TNM staging is aprognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 61:665-677
13. Chang JC, Wooten EC, Tsimelzon A et al (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369
14. Collette L, Bosset JF (2007) Adjuvant chemotherapy following neoadjuvant therapy of rectal cancer. The type of neoadjuvant therapy (chemoradiotherapy or radiotherapy) may be important for selection of patients. In reply. J Clin Oncol 26:508-509
15. Collette L, Bosset JF, Dulk M den et al (2007) Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemtherapy? A trial of the European organisation for research and treatment of cancer radiation oncology group. J Clin Oncol 25:4379-4386
16. Croner RS, FÖrtsch T, Brückl WM et al (2008) Molecular signature for lymphatic metastasis in colorectal carcinomas. Ann Surg 247:803-810
17. De Roock W, Piessevaux H, De Schutter J et al (2008) KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19:508-515
18. De Vries, Jong S de (2008) Eploiting the apoptotic route for cancer treatment: a single hit will rarely result in a home run. J Clin Oncol 26:5151-5153
19. Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712
20. Fang JY, Richardson BC (2005) The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6:322-327
21. Fernandez-Martos C, Pericay C, Aparicio J et al (2010) Phase II, randomized study of concomitant chemotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 Study. J Clin Oncol 28:859-865
22. Fietkau R, Barten M, Klautke G et al (2006) Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. Dis Colon Rectum 49:1284-1292
23. Gaedcke J, Grade M, Jung K et al (2010) KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 94:76-81
24. Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620-4625
25. Ghadimi BM, Grade M, Difilippantonio MJ et al (2005) Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23:1826-1838
26. Gianni L, Zambetti M, Clark K et al (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265-7277
27. Glimelius B, Oliveira J (2009) ESMO Guidelines Working Group. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 (Suppl 4):54-56
28. Glynne-Jones R, Mawdsley S, Harrison M (2010) Cetuximab and chemoradiation for rectal cancer - is the water getting muddy? Acta Oncol 49(3):278-286
29. Grade M, Gaedcke J, Wangsa D et al (2009) Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy. Cancer Genet Cytogenet 193(1):19-28
30. Grade M, Ghadimi BM, Varma S et al (2006) Aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt/beta-catenin signaling pathway in human rectal carcinomas. Cancer Res 66:267-282